Receptor, Fibroblast Growth Factor, Type 1
"Receptor, Fibroblast Growth Factor, Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM.
MeSH Number(s)
D08.811.913.696.620.682.725.400.177
D12.776.543.750.060.440
D12.776.543.750.750.400.370.500
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 1".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 1 [D08.811.913.696.620.682.725.400.177]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, Fibroblast Growth Factor, Type 1 [D12.776.543.750.060.440]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 1 [D12.776.543.750.750.400.370.500]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 1".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 1" by people in Harvard Catalyst Profiles by year, and whether "Receptor, Fibroblast Growth Factor, Type 1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 0 | 2 | 2 |
1999 | 0 | 2 | 2 |
2000 | 0 | 2 | 2 |
2001 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2003 | 0 | 3 | 3 |
2004 | 0 | 6 | 6 |
2005 | 1 | 0 | 1 |
2006 | 3 | 0 | 3 |
2007 | 0 | 3 | 3 |
2008 | 1 | 3 | 4 |
2009 | 4 | 6 | 10 |
2010 | 2 | 3 | 5 |
2011 | 3 | 2 | 5 |
2012 | 1 | 3 | 4 |
2013 | 5 | 1 | 6 |
2014 | 3 | 4 | 7 |
2015 | 3 | 5 | 8 |
2016 | 5 | 2 | 7 |
2017 | 2 | 7 | 9 |
2018 | 8 | 1 | 9 |
2019 | 8 | 5 | 13 |
2020 | 2 | 5 | 7 |
2021 | 3 | 3 | 6 |
2022 | 0 | 2 | 2 |
2023 | 0 | 4 | 4 |
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 1" by people in Profiles.
-
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation. Acta Neuropathol. 2023 Dec 08; 147(1):2.
-
Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer. J Clin Invest. 2023 11 01; 133(21).
-
How human genetic context can inform pathogenicity classification: FGFR1 variation in idiopathic hypogonadotropic hypogonadism. Hum Genet. 2023 Nov; 142(11):1611-1619.
-
FGFR1 gene fusions in a subset of pediatric mesenchymal tumors: Expanding the genetic spectrum of tumors sharing histologic overlap with infantile fibrosarcoma and "NTRK-rearranged" spindle cell neoplasms. Genes Chromosomes Cancer. 2023 11; 62(11):641-647.
-
Proteomic analysis reveals dual requirement for Grb2 and PLC?1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation. Oncotarget. 2022; 13:659-676.
-
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology. 2022; 11(1):2021619.
-
Biologically informed deep neural network for prostate cancer discovery. Nature. 2021 10; 598(7880):348-352.
-
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov. 2022 02; 12(2):402-415.
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
-
MHC class I H2-Kb negatively regulates neural progenitor cell proliferation by inhibiting FGFR signaling. PLoS Biol. 2021 06; 19(6):e3001311.